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The kinetics of amyloid beta turnover within human brain is still poorly understood. We
previously found a dramatic decline in the turnover of Aβ peptides in normal aging. It was not
known if brain interstitial ﬂuid/cerebrospinal ﬂuid (ISF/CSF) ﬂuid exchange, CSF turnover,
blood-brain barrier function or proteolysis were affected by aging or the presence of β
amyloid plaques. Here, we describe a non-steady state physiological model developed to
decouple CSF ﬂuid transport from other processes. Kinetic parameters were estimated using:
(1) MRI-derived brain volumes, (2) stable isotope labeling kinetics (SILK) of amyloid-β
peptide (Aβ), and (3) lumbar CSF Aβ concentration during SILK. Here we show that changes
in blood-brain barrier transport and/or proteolysis were largely responsible for the agerelated decline in Aβ turnover rates. CSF-based clearance declined modestly in normal aging
but became increasingly important due to the slowing of other processes. The magnitude of
CSF-based clearance was also lower than that due to blood-brain barrier function plus proteolysis. These results suggest important roles for blood-brain barrier transport and proteolytic degradation of Aβ in the development Alzheimer’s Disease in humans.
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table isotope-labeling kinetics (SILK) in humans have previously revealed that: (1) the turnover rate of Aβ42 (FTR42)
relative to Aβ40 (FTR40) increases in both sporadic Alzheimer’s disease (AD) and autosomal dominant Alzheimer’s
Disease (ADAD), likely due to active deposition of Aβ42 into
plaques; (2) the production rate of Aβ42 relative to Aβ40 increases
in ADAD; and (3) the turnover rates of Aβ peptides decrease with
age1–3. One weakness of the previous analysis was the assumption
that the system was at a steady state. As such, the kinetic models
could not account for the effects of secretase inhibitors4–6, or
explain the rise in the lumbar cerebrospinal ﬂuid (CSF) concentration of Aβ peptides observed during the 36–48 h SILK
studies7–10. Other existing non-steady-state models do not
address the concentration rise observed in SILK studies11–17.
The goal of this approach is to more accurately model Aβ
peptide kinetics in the central nervous system (CNS). Myriad
processes affect Aβ turnover in the brain, including transport
across the blood–brain barrier, enzymatic/lysosomal degradation,
interaction and deposition into plaques, and the complex ﬂow
and exchange of CSF and interstitial ﬂuid (ISF)1,18–20. Ideally,
brain tissue or ISF would be sampled. However, such procedures
are highly invasive21. Our approach was to use subject-speciﬁc
MRI-derived CNS compartment volumes to better model transport of CSF from the cranial subarachnoid space (SAS) to the
lumbar SAS. Although we do not directly measure or model
“glymphatic” ﬂuxes (i.e., ﬂow within the perivascular space and
brain interstitium resulting in mixing of CSF and ISF), we can
infer these ﬂuxes via the model, because the ﬂux of Aβ transferred
from ISF to CSF will equal the ﬂux of Aβ lost from the CSF. CSF
is lost from the CNS via arachnoid granulations, dural lymphatics, at the cribriform plate, and down cranial or spinal nerves20.
These exit processes, involving bulk ﬂuid ﬂow of CSF, affect the
Aβ concentration throughout the SAS, including at the lumbar
sampling site. Via the combination of kinetic measurements, MRI
volumes and CSF concentration rises upon CSF withdrawal in
humans, we can estimate the turnover of Aβ in CSF and thus
infer the ﬂux of Aβ from ISF to CSF and the rate of irreversible
loss of Aβ from within the ISF.
Glymphatics is deﬁned by Nedergaard et al. as “astrocytemediated transport of CSF and ISF that clears metabolic waste
from the interstitial space of the brain parenchyma primarily
during non-REM (nonrapid eye movement) sleep and states of
high slow-wave activity. This process serves a pseudolymphatic
function in the CNS”22. Others argue that aquaporin-4 deletion
does not affect dye penetration into the paravascular space and
surrounding parenchyma23. Some have observed that transport
through brain parenchyma is molecular-weight dependent suggesting a dominant role for molecular diffusion versus convective
ﬂow17,24–27. Correctly modeling the tortuous ﬂow in the presence
of cardiac-driven pressure ﬂuctuations through the highly cellular
cortex and dense extracellular matrix is daunting, and the current
approach is desirable as it is largely if not entirely agnostic to the
exact mechanism of the “glymphatic” process.
CSF ﬂow in the CNS is generally directed from the choroid
plexus to the superior sagittal sinus, although this is a
simpliﬁcation28,29. Each heartbeat and breath also induces substantial oscillatory CSF ﬂow30–32. The complicated ﬂow patterns
of the CSF resulting from these pulsations are observable by MRI
velocimetry and enhance mass transport in the CNS33–35. The
presence of trabeculations and nerve roots passing through the
SAS result in complicated, time-dependent recirculation
patterns15,36. The trabeculations and nerve roots are similar to
bafﬂes, which are known in the ﬁeld of reactor engineering to
enhance ﬂuid mixing37. Accurate ﬂow analysis by computational
ﬂuid dynamics is impractical without higher-resolution imaging,
so the model presented here assumes that oscillatory CSF ﬂow
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results in the perfect mixing of ﬂuids within distinct compartments in the SAS. This simpliﬁcation is consistent with our
previous compartmental model that ﬁt the SILK data exceptionally well1,2. The model accounts for changes in lumbar space
volume due to the hourly withdrawal of CSF from the lumbar
space and potential CSF leaks due to the indwelling catheter,
which is perhaps the most important feature of the model.
It is believed that the rate of nucleation and growth of amyloid
plaques depends upon the concentration of Aβ42 in the cortical
interstitial ﬂuid12,38. Thus, changes in the rate of clearance of
Aβ42 from the cortical interstitial ﬂuid may be a critical factor in
the onset of plaque formation, just as differences in the rate of
production of Aβ42 affect the age of onset of Alzheimer’s disease1.
In this study, we estimate the rates of clearance of Aβ in cortical
interstitial ﬂuid due to different processes, such as transport
across the blood–brain barrier, proteolysis, and deposition into
plaques. Transport of Aβ42 across the blood–brain barrier is
mediated by lipoprotein-related protein 1 (LRP-1)39, leading to
the transfer of Aβ42 from the brain interstitial ﬂuid to the blood40.
Binding of Aβ40 and Aβ42 to LRP-1 is saturable and clearance
across mouse brain capillaries is blocked by antibodies against
LRP-141. Expression of LRP-1 declines in aging rats and is
negatively correlated with the concentration of Aβ40 and Aβ42 in
rat brain cortex homogenates42. Multiple enzymes contribute to
the proteolysis of Aβ42 within the CNS, including secreted and
membrane-bound enzymes such as an angiotensin-converting
enzyme, neprilysin, insulin-degrading enzyme and various
MMPs, in addition to degradation downstream of endocytosis or
phagocytosis by cells, particularly microglia and monocytederived macrophages43. Transport across the BBB, enzymatic
degradation and deposition into plaques within the brain will
result in similar kinetics for isotope-labeled Aβ, as all processes
likely exhibit close to ﬁrst-order kinetics and occur within the
same compartment. In contrast, transfer of Aβ from ISF to CSF
will result in elimination of Aβ by processes governed by CSF
turnover kinetics. CSF-based processes will affect the shape of the
SILK curves differently from processes that occur within the ISF,
and this provides the rationale for the current study.
Results and discussion
Correlation of MRI-derived volumes with age and steady-state
model parameters. CNS volumes were recorded by MRI for
100 study subjects who also completed SILK kinetic studies, with
four subjects excluded due to poor ﬁts of the model to SILK or
lumbar concentration data. All of the subjects were part of earlier
published studies1,2. Subject demographics, lumbar CSF tau and
Aβ concentrations, and results from the previous steady-state
model are shown in Supplementary Tables 1 and 2. Correlations
of MRI-measured CNS volumes with amyloid status were consistent with ﬁndings in the literature (Supplementary
Table 3)44–47. Amygdala, hippocampus, and precuneus volumes
declined most dramatically due to β-amyloidosis. Total ventricle
volume was increased in amyloid-positive subjects, while the total
gray volume decreased. The effects of normal aging on CNS
volumes and thicknesses were assessed in amyloid-negative subjects to eliminate effects of β-amyloidosis (Supplementary
Table 4). Putamen, accumbens-area, thalamus, and hippocampus
volumes declined most dramatically with age, as expected.
Development of a subject-speciﬁc physiological model. A new
physiological model was developed to decouple transport of Aβ
peptides within CSF from (1) transport across the blood–brain
barrier, (2) changes in proteolytic degradation, and (3) deposition
into plaques. The new physiological model (Fig. 1a) assumed that
the CNS consists of the following compartments: (1) cells
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Fig. 1 Model of Aβ production, transport, and clearance. Physiological model of CNS during SILK study, incorporating ﬂuid ﬂows, ISF and CSF
compartment volumes, and Michaelis–Menten kinetics for Aβ production. a Model structure. b Flows in the spinal SAS due to hourly CSF withdrawal. The
volume of the lumbar SAS decreases when the CSF withdrawal rate QLP exceeds the CSF production rate (QCSF) and subsequently reﬁlls with CSF to its
original volume. c Timeline of hourly CSF withdrawal. d Net ﬂow in the spinal SAS. e Bidirectional ﬂow in the spinal SAS.

producing Aβ via enzymatic reactions at their plasma membranes
following Michaelis–Menten kinetics, (2) brain ISF, (3) cranial
subarachnoid space (SAS), (4) cisternal and ventricular SAS, and
(5) spinal SAS divided into cervical, thoracic and lumbar regions.
The model was written as a nonlinear system of 51 ordinary
differential equations (Supplementary Methods 1). Parameter
optimization and differential equation solving were performed in
Julia48–50. The volumes of compartments were estimated from

Freesurfer analysis of MRI scans (Supplementary Methods 2).
The spinal volumes were not measured in this study and literature values were assumed for the spinal SAS volumes (VSP1 ≈
cervical SAS, VSP2 ≈ thoracic SAS, VSP3 ≈ lumbar SAS)51–53. In
addition, a range of CSF volumes was examined to discover the
best ﬁt to the observed change in lumbar concentration of Aβ
during the course of the 36–48 h SILK experiment. Transfer
between compartments was modeled as volumetric ﬂows (mL/h),

COMMUNICATIONS BIOLOGY | (2022)5:98 | https://doi.org/10.1038/s42003-022-03037-0 | www.nature.com/commsbio

3

ARTICLE

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-022-03037-0

which were divided by the volumes of the compartments to
obtain ﬁrst-order rate constants for mass transfer between
compartments.
CSF production was assumed to entirely arise from the choroid
plexus, speciﬁed as the CSF production rate QCSF. During the SILK
study, 6 mL of CSF were withdrawn every hour from an
indwelling lumbar catheter. The withdrawal occurred over
5–10 min. During the hourly CSF collection, the CSF withdrawal
rate (QLP) was much greater than the model-predicted CSF
production rate (QCSF) in all subjects. It was thus assumed that the
volume of the lumbar space (VSP3) decreased during withdrawal
(Fig. 1b–e), which has been observed in humans by MRI during
lumbar puncture51. After CSF withdrawal, CSF production served
to reﬁll the lumbar space to its original volume. Although the
majority of CSF was assumed to be reabsorbed within the cranial
compartment, some amount of CSF was assumed to be lost down
spinal nerves (QSN)54. Qosc and Qglymph are bidirectional
continuous ﬂows that approximate the oscillatory ﬂows due to
the cardiac and respiratory cycles. For some subjects with large
lumbar CSF Aβ concentration rises, the data were better ﬁt
assuming a leak due to catheterization (Qleak). Further details of
the model are provided in Supplementary Methods 1.
The lumbar CSF concentration rise of Aβ peptides was
substantial (Fig. 2 and Supplementary Fig. 1), with a mean rise
of 27% between 0 and 36 h. All experiments began at 8 a.m.
(time = 0) and a dip in the lumbar concentration of Aβ peptides
was seen during the nighttime and following morning, which has
been previously associated with the effects of sleep9,10. However,
sleep was not modeled in this study as the sleep-wake cycle was
not controlled and was not apparent in 19 out of 96 subjects. In
this study, the subjects arose early (how early was uncontrolled)
to reach the hospital by 7 a.m. and the study was started at 8 a.m.
They were instructed to remain mostly in bed for 36–48 h and
could sleep/nap at will. Of the 77 subjects that showed a sleep
effect, many showed abbreviated dips, double dips, or prolonged
dips in the lumbar Aβ concentration. SILK and concentrationtime courses for all 96 subjects are presented in Supplementary
Data 3. To reduce the effect of sleep on the conclusions,
concentration data was not ﬁt to the model between 11 p.m. and
11 a.m., accounting for transport delays between ISF and the
lumbar space. The sleep effect also overlapped with the ﬁrst three
hours of the experiment.
The physiological model predicted a lumbar Aβ concentration
rise of 12% between 3 and 36 h (see VCSF 100% curve in Fig. 2a and
Qleak = 0 mL/h curve in Fig. 2b). This was lower than both the mean
and median concentration rises between 3 and 36 h (19% and 17%,
respectively). The total CSF volume and/or the spinal CSF volume
were thus systematically varied to improve the ﬁt of the model to the
observed concentration rise, selecting the simulation with the lowest
sum-of-squares residual. For 20 out of 96 subjects, the concentration
rise was greater than that predicted even if the total CSF volume was
decreased by 50%. For these subjects, an additional parameter was
added, Qleak, which represented continual leakage of CSF around the
indwelling catheter. A leak was also assumed for the seven subjects
with clinical records of a blood patch to seal a CSF leak. Qleak was
not different by amyloid status but did signiﬁcantly decrease with
age (Table 1 and Supplementary Table 5). For ten of the subjects, the
leak rate appeared to change at speciﬁc points during the 36–48 h
experiment, and Qleak was allowed to change to better ﬁt the data
(for example, see Fig. 3). Fits to SILK and lumbar concentration data
for all 96 subjects are included as Supplementary Data 3.
Kinetic results from the physiological model. The parameter
kBPD describes irreversible loss in the ISF compartment by processes that include: (1) transport across the blood–brain barrier
4

(“B”), (2) proteolytic degradation (“P”), and (3) permanent
deposition into plaques (“D”). kBPD is similar to FTR from the
steady-state model, but the effects of CSF transport are modeled
explicitly, which should allow kBPD to more accurately represent
processes that occur in the brain ISF. Like FTR, both kBPD38 and
kBPD40 were highly correlated with age in amyloid-negative subjects (Table 1 and Fig. 4a). Unlike FTR, kBPD38 and kBPD40 are not
correlated with age in the amyloid-positive subject (Fig. 4b).
However, the CSF production rate (QCSF) was negatively correlated with age in amyloid-positive subjects (r = −0.42,
P = 0.0079, n = 38) but not in amyloid-negative subjects
(r = −0.0062, P = 0.96, n = 58). This implies that changes in Aβ
clearance in normal aging are driven by changes in blood–brain
barrier transport or proteolysis (deposition should be minimal in
normal aging). Aβ clearance in amyloid-positive subjects appears
to be inﬂuenced by changes in CSF production, and potentially
from the substantial decrease in brain parenchymal volumes and
increase in ventricle volume (Supplementary Table 3).
kBPD38 and kBPD40 are signiﬁcantly lower in amyloid-positive
subjects after controlling for age (Table 1). However, kBPD42 is
signiﬁcantly higher in amyloid-positive subjects, as is the ratio
kBPD42/kBPD40 (Table 1 and Fig. 4c). This mirrors the ﬁnding from
the steady-state model that the turnover of Aβ42 was elevated in
amyloid-positive subjects relative to Aβ40. Because transport and
proteolysis rates of Aβ40 and Aβ42 are expected to be similar, the
increased clearance of Aβ42 is believed to represent deposition of
Aβ42 into plaques1,2. The ratio kBPD42/kBPD40 is not correlated
with age in amyloid-negative subjects (Table 1) or in amyloidpositive subjects (r = −0.29, P = 0.073, n = 38).
The forward rate constant for reversible exchange in the ISF
compartment (kex42) was signiﬁcantly higher in amyloid-positive
subjects (Table 1). It is hypothesized that soluble Aβ42 becomes
temporarily insoluble sometime between production and clearance. The greater magnitude in subjects with AD implies a role
for plaques in this process2. Isotope labeling of plaques has also
been observed in SILK subjects postmortem55.
With certain presenilin mutations, the rate of production of
Aβ42 is expected to be elevated relative to the rate of production
of Aβ40, which was indeed observed with the steady-state model1.
However, the steady-state model also exhibited a strong
correlation between the production rate ratio of Aβ42 to Aβ40
and the lumbar CSF concentration ratio [Aβ42]lumbar /[Aβ40]lumbar
(Supplementary Fig. 2a). This would require a highly speciﬁc
change in the kinetics of secretases in AD, or changes in
intracellular trafﬁcking that selectively decreased the rate of
production of Aβ42 relative to Aβ40, which both seem unlikely. In
the physiological model, the Vmax of gamma-secretase for the
production of Aβ42 (Vmax,γ42) was determined relative to Vmax,γ40,
with Vmax,γ40 ﬁxed for all subjects to a literature-derived
value56,57. Vmax,γ42 was thus normalized by Vmax,γ38 instead of
Vmax,γ40. The production rate ratio of Aβ42 relative to Aβ38 by
gamma-secretase was elevated in presenilin mutation carriers
compared to amyloid negatives and amyloid positives (Fig. 4d).
There was no difference in the relative production rate based on
amyloid status, as expected, and in contrast to the steady-state
model (Supplementary Fig. 2b). Without normalization, Vmax,γ42
was higher in mutation positives versus amyloid negatives as
expected, but the comparison with amyloid positives did not
reach signiﬁcance (Supplementary Fig. 2c).
The production rate of APP (kf) declined with age, perhaps
related to the decline in total gray volume (Table 1) and a loss of
synaptic activity58–60. The production rate of APP was also
compared between presenilin mutation carriers and sibling nonmutation-carrier controls (Table 2). In these age-matched
subjects, the production rate of Aβ42 increased due to the
presence of presenilin mutations, but kf was not different.
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Fig. 2 Increasing lumbar Aβ CSF concentration due to hourly CSF withdrawal. Normalized lumbar CSF concentrations of Aβ peptides averaged over all
subjects (n = 96). Lumbar CSF Aβ concentration time courses for each subject were ﬁrst normalized to time = 3 h to account for the sleep effect from the
previous night (experiments started at 8 a.m.). The Aβ concentration was the average of Aβ38, Aβ40, and total Aβ for each subject (total Aβ was from an
immunoprecipitation with an antibody recognizing a sequence common to Aβ38, Aβ40, and Aβ42). Some subjects (n = 17) only had concentration
timecourse measured by ELISA for Aβ40 and Aβ42. The ELISA time courses were averaged for these two peptides at each time point. a The total volume of
CSF (VCSF) was scaled between 50 and 125% in separate simulations, and the volume of spinal CSF was varied from 40 to 80 mL. b The presence of a CSF
leak around the catheter was also simulated, ranging from 0 to 20 mL/h, or equal to the entire CSF production rate (Qleak = QCSF). Medians and means of
measurements are shown, and bars represent the interquartile range. Shaded areas represent the sleep effect. Simulations of CSF leaks equal to 20 mL/h
or QCSF overlapped with Qleak = 15 mL/h. For the full boxplot of measured concentrations, see Supplementary Fig. 1.

The CSF production rate QCSF should be identical to the CSF
production rate typically measured by, for example, the modiﬁed
Masserman method61. QCSF did not differ by amyloid status
(Table 1). The mean values were similar to those found in a
carefully performed study in which the CSF production rate was
found to be 24.0 ± 5.00 mL/h (95% CI: 16.2–33.8 mL/h)62. The
CSF production rate has been found to decline with age61. QCSF
did not vary signiﬁcantly with age in amyloid-negative subjects
(Table 1). CSF pressure transients and thus CSF production rate
were not measured during the data collection and the CSF
production rate is inferred from the data. Our mode of

measurement is not as precise and the decrease is not detected.
However, on average, the CSF production rates are reasonable
and arise from the model structure and data without being ﬁt. In
addition, amyloid subjects under 60 years in age show a greater
CSF production rate than those over 60, but it is not signiﬁcant
(P = 0.2; Supplementary Table 6). However, QCSF did decline
with age in amyloid-positive subjects, as mentioned previously.
The physiological model accounts for the oscillatory ﬂow of
CSF driven by circulatory and respiratory pulsations. The
oscillatory ﬂow was modeled as a continuous bidirectional ﬂow
with magnitude Qosc. Qosc did not differ between AD and non-AD
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Table 1 Model results.
Predicted marginal means (S.E.) at age = 69.9 y

CSF leak
Aβ clearance

Aβ production (w/o
mutation carriers)
APP production (w/o
mutation carriers)
Exchange
CSF ﬂuid ﬂow

Flux Aβ38
Flux Aβ40
Flux Aβ42

Qleak > 0?
Qleak (mL/h)
kBPD38 (h−1)
kBPD40 (h−1)
kBPD42 (h−1)
kBPD42/kBPD38
kBPD42/kBPD40
kBPD40/kBPD38
Vmax,γ42/Vmax,γ38
Vmax,γ42 (μg/(mL·h))
kf (ng/h)
Total gray volume (mL)
kex42 (h−1)
QCSF = Qglymph (mL/h)
Qosc (mL/h)
[Aβ40]ISF/[Aβ40]lumbar
Predicted cisternography halflife (h)
VCSF (mL)
CSF-based (ng/min)
BBB + proteolysis (ng/min)
% CSF-based
CSF-based (ng/min)
BBB + proteolysis (ng/min)
% CSF-based
CSF-based (ng/min)
BBB + proteolysis (ng/min)
Deposition (ng/min)
% CSF-based

Amyloid negative
(N = 58)

Amyloid positive
(N = 38)

P valuea

20/58
2.6 (0.6)
0.31 (0.02)
0.37 (0.03)
0.53 (0.06)
2.1 (0.4)
1.7 (0.3)
1.36 (0.08)
1.02 (0.04)b
125 (5)b
3500 (300)b
590 (8)b
0.06 (0.02)
23 (1)
8.8 (0.8)
10.1 (0.8)
20.7 (0.6)

10/38
2.6 (0.8)
0.22 (0.03)
0.24 (0.03)
0.96 (0.07)
5.3 (0.5)
4.8 (0.4)
1.1 (0.1)
1.07 (0.06)c
139 (8)c
3400 (500)c
570 (10)c
0.17 (0.02)
26 (2)
11 (1)
10 (1)
19.8 (0.7)

300 (10)
3.1 (0.4)
4.9 (0.4)
43 (3)
14 (2)
28 (2)
39 (2)
2.2 (0.2)
4.1 (0.4)
1.4 (0.4)
33 (2)

310 (10)
3.4 (0.5)
3.2 (0.5)
52 (3)
17 (2)
16 (3)
50 (3)
1.7 (0.3)
1.6 (0.5)
4.6 (0.5)
22 (3)

Correlation coefﬁcient
with age
Amyloid negative
(N = 58)

P value

0.40*
0.92
0.015
0.0024
<0.0001
<0.0001
<0.0001
0.10
0.52
0.15
0.79
0.15
<0.0001
0.31
0.16
0.85
0.32

−0.36
−0.68
−0.59
−0.27
0.24
0.13
0.21
0.28b
0.34b
−0.58b
−0.42b
0.087
−0.0062
0.47
−0.51
−0.30

0.0050
<0.0001
<0.0001
0.044
0.069
0.33
0.11
0.039
0.013
<0.0001
0.0014
0.52
0.99
<0.0001
<0.0001
0.021

0.47
0.54
0.0082
0.037
0.29
0.0037
0.0042
0.19
<0.0001
<0.0001
0.0014

0.38
−0.24
−0.81
0.47
−0.33
−0.76
0.45
−0.30
−0.70
−0.21
0.33

0.0030
0.070
<0.0001
<0.0001
0.011
<0.0001
<0.0001
0.021
<0.0001
0.11
0.012

*Chi-square statistic = 0.71.
at test of predicted marginal means (least-squares means) except where noted by *. See Supplementary Table 5 for interactions between age and amyloid status; italic values signify: P < 0.05; bold italic
values signify: P < 0.01.
bN = 54.
cN = 33.

subjects (Table 1). Qosc increased with age, while the ISF-tolumbar concentration “gradient” [Aβ40]ISF/[Aβ40]lumbar decreased
with age (Table 1), consistent with previous observations in
humans61. The concentration gradient is highly positively
correlated with 1/Qosc1/2 (r = 0.82, P = 1.3 × 10−24, n = 96). Qosc
is mathematically similar to a diffusion coefﬁcient and higher
values will tend to decrease the ISF/lumbar concentration
gradient. It is known that the total cerebral blood ﬂow decreases
in aging, as does the cervical CSF stroke volume63. This suggests
that the enhanced mixing of CSF that decreases the ISF/lumbar
gradient in aging is due to biomechanical factors other than CSF
pulsatility. The increase in Qosc with age may be similar to the
increase in pulse wave velocity with age due to stiffening of the
arteries64. Although ISF-to-lumbar gradients can be inferred from
experiments, there is scant evidence of a ventriculo-lumbar
gradient for Aβ21,65, in contrast to the negative gradient for brain
proteins such as tau and the positive gradient for blood proteins
such as albumin66.
Allowing bidirectional ﬂow results in mass transfer down
concentration gradients. For example, within the model, the
introduction of a labeled species in the lumbar space results in
eventual transport of the label to the brain, similar to
cisternograpy and related MRI-based CNS tracer studies54,67,68.
Although the study protocol did not include cisternography, the
model makes speciﬁc predictions about the distribution and
disappearance of label within the CNS. This includes a prediction
6

of a “cisternography half-life”, the half-life in the CNS of a labeled
compound introduced into the lumbar space. Moriyama et al.
studied the effects of age on cisternography half-life and
developed a linear regression model67. The Moriyama et al.
model predicted a mean cisternography half-life for the subjects
in our study of 20 ± 2.4 h, compared to 21 ± 4.5 h predicted by the
physiological model. The predicted cisternography half-life was
strongly inﬂuenced by the exit of CSF from the CNS down spinal
nerves and this was used to ﬁx QSN at 10% of QCSF for all subjects.
Higher or lower values of QSN resulted in unreasonable values for
the predicted cisternography half-life (Supplementary Fig. 3). The
chosen value for QSN was slightly lower than previous estimates
(12–25% of QCSF)69. Although the observed increase in Qosc with
age would tend to decrease the cisternography half-life, the
increase in the total volume of CSF (VCSF) with age seems to
negate this effect (Table 1). While cisternography data is useful
for imaging tracer in the entire CNS simultaneously, modern
methods such as glymphatic MRI can contribute more reﬁned
spatial information that will be useful in the development of
future versions of the model with more accurate geometric
modeling of the CNS70–72.
Flux of Aβ through distinct pathways. The concentrations and
ﬂuxes of Aβ peptides within ISF are difﬁcult to measure in
humans. The measured Aβ40 concentration in homogenized
cortex varies widely but tends to be in the range of 1–10 ng/g wet
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Fig. 3 Example of model ﬁts to SILK and lumbar Aβ concentration. The physiological model ﬁts with step changes in Qleak at 3 h and 20 h for a single
amyloid-positive subject. a Fit of the physiological model to SILK data. Blue = Aβ38, green = Aβ40, red = Aβ42. b Fit of lumbar CSF concentration data
(0 < time < 3, Qleak = 8 mL/h; 3 < time ≤ 20 h, Qleak = 0 mL/h; 20 ≤ time < 30 h, Qleak = 13 mL/h; time ≥ 30 h, Qleak = 0 mL/h). Blue circles = mass
spectrometric measurements normalized to time = 3 h. Red circles = moving mean smoothed data. c Lumbar CSF concentrations were measured by
immunoprecipitation followed by quantitative mass spectrometry, showing the abrupt change in concentration at about 27 h for all four peptides measured.
d Lumbar CSF concentrations measured by ELISA also showed an abrupt change at about 27 h for both peptides measured.

cortical tissue40,73–75, although some studies report much higher
values76–78. APP is an integral membrane protein and Aβ peptides are predominantly extracellular79 (particularly when considering endosomes and lysosomes to be topologically
extracellular). Assuming a cellularity of the cortex of ~90%80, this
suggests that cortical ISF concentrations are about 10× higher
than concentrations measured in the homogenized cortex. The
physiological model speciﬁcally incorporates the volume of gray
matter ISF, and the mean rise in Aβ40 concentration from lumbar
SAS to brain ISF ([Aβ40]ISF/[Aβ40]lumbar) was about tenfold and
did not differ by amyloid status (Table 1). However, the concentration of Aβ in homogenized cortex should be about tenfold
lower than the concentration in brain ISF. Using this assumption,
the physiological model predicted a concentration of Aβ40 in the
homogenized cortex of 6.6 ± 3.5 ng/g wet tissue, within the range
of typical values (assuming a density of the cortex tissue of 1.03 g/
mL81). However, using microdialysis, the concentration of Aβ in
the brain ISF is about the same as in ventricular and lumbar CSF,
and this is more than an order of magnitude lower than the value
predicted by the physiological model21,82. Given the dramatic
concentration rise observed during sustained withdrawal of
lumbar CSF, some ﬂuid within the CNS must have a higher
concentration of Aβ and this is likely the ISF. This suggests that
microdialysis
measurements
underreport
the
ISF
concentration of Aβ.
The ﬂux of Aβ40 peptides from the CNS into blood was
previously reported as 9.7 ng/min, which was found by measuring
the venous–arterial Aβ concentration difference during inferior
petrosal sinus sampling40. This ﬂux should include Aβ

transported to the venous system by CSF absorption at the
superior sagittal sinus and Aβ transported across the blood–brain
barrier. It should not include Aβ transported to the lymphatic
system via CSF absorption at the dura, cribriform plate, or via
perivascular transport20. The physiological model predicted a
mean Aβ40 ﬂux of 15 ± 13 ng/min due to CSF absorption in all
subjects according to Eq. (1).
Flux of Aβ40 by CSF absorption ¼ Qcrainal ´ ½Aβ40 cranial þ Qspinalnerve ´ ½Aβ40 spinal

ð1Þ
A key feature of glymphatics is the entrance of CSF along
periarterial pathways and ISF exit along perivenous pathways83.
The ﬂux of Aβ40 peptides from the brain ISF into the CSF is given
by Eq. (2). Due to mass balance, Eqs. (1) and (2) must be equal at
steady state or pseudo-steady state.
Flux of Aβ40 from ISF to CSF ¼ Qglymph ´ ð½Aβ40 ISF  ½Aβ40 cranial Þ
ð2Þ
The mean rate of irreversible loss of Aβ40 peptides by transport
across the BBB or via proteolysis is predicted by the physiological
model to be 25 ± 28 ng/min (Eq. (3)). This is greater than the
experimentally measured value from inferior petrosal sinus
sampling, suggesting that at least 60% of Aβ40 is cleared from
the brain by proteolysis. The amount of CSF that is absorbed at
arachnoid granulations is controversial and may be quite low84.
In that case, the vast majority of Aβ measured during inferior
petrosal sinus sampling would represent transport across the
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Fig. 4 Derived Aβ production and clearance rate constants. Aβ clearance and production rate constants. a The rate constant describing the irreversible
loss of Aβ peptides from the brain ISF compartment (kBPD) signiﬁcantly declined with age in amyloid-negative subjects for Aβ38 and Aβ40 (n = 58; also see
Table 1). b The age effect on kBPD38 and kBPD40 was absent in amyloid-positive subjects (n = 38). c The rate of irreversible loss of Aβ42 (kBPD42) was elevated
relative to Aβ40 (kBPD40) in the presence of amyloid plaques, as evidenced by elevated PET PIB MCBP (n = 77). This elevation likely represented active
deposition of Aβ42 into plaques, and a cutoff of 1.3 (horizontal dashed line) distinguishes most plaque-bearing subjects from non-plaque-bearing subjects.
Declining ratios of lumbar CSF Aβ42 to Aβ40 are a hallmark of AD, with a cutoff of 0.12 in common use (vertical dashed line). See statistical comparisons in
Table 1. d The gamma-secretase production rate constant ratio Vmax,γ42/Vmax,γ38 reﬂects the kinetics of gamma-secretase toward the production of Aβ42
relative to Aβ38. The production rate ratio did not differ by amyloid status, but presenilin mutation carriers had elevated production of Aβ42 relative to Aβ38
as compared to both groups of non-mutation carriers. ANOVA with Tukey post hoc analysis.

Table 2 Production rates in presenilin mutation carriers and age-matched non-carriers.

Age
kf (ng/h)
Vmax,γ42 (μg/(mL h))
Vmax,γ42/ Vmax,γ38
Total gray volume (mL)
at

Mutation-carrier mean (S.E.) N = 9

Sibling non-carriers mean (S.E.) N = 10

P valuea

45
8000
1.6
160
600

49
8000
0.80
85
640

0.61
0.99
0.0079
0.0014
0.14

(4)
(1000)
(0.2)
(20)
(20)

test; values in italics signify P < 0.05; values in bold italic signify: P < 0.01.

blood–brain barrier.
Flux of Aβ40 via BBB transport; proteolysis and deposition ¼ kBPD40 ´ ½Aβ40brain xV brainISF

ð3Þ
The model predicts that the ﬂuxes of Aβ peptides across the BBB
and via proteolysis decrease dramatically in normal aging (Fig. 5a,
b). However, the presence of amyloid plaques depresses BBB and
proteolysis ﬂuxes (Table 1) and mutes the age effect (Fig. 5a, b). In
stark contrast, the CSF-based ﬂux and thus the ISF-to-CSF ﬂux was
only weakly correlated with age (Fig. 5c, d). However, the CSF-based
and ISF-to-CSF ﬂux became more important with age, mostly
because of the dramatic decline in BBB and proteolysis ﬂuxes
(Fig. 5e). By amyloid status, the fraction of Aβ clearance that was
8

(5)
(1000)
(0.05)
(3)
(10)

due to ISF-to-CSF transfer increased for Aβ38 and Aβ40 but
decreased for Aβ42 (Table 1). The decrease of Aβ42 in amyloidpositive subjects (Fig. 5f) is likely related to the large deposition ﬂux
of Aβ42 in the presence of amyloid plaques (Table 1). The
magnitudes of the pathways also differed in amyloid-negative
subjects. CSF-based ﬂux of Aβ38 was 3.1 (0.3) ng/h, while
BBB + proteolysis ﬂux was 5.5 (0.7) ng/h (n = 58; P = 0.003).
CSF-based ﬂux of Aβ40 was 14 (2) ng/h, while BBB + proteolysis
ﬂux was 31 (4) ng/h (n = 58; P = 0.0005). CSF-based ﬂux of Aβ42
was 2.2 (0.2) ng/h, while BBB + proteolysis ﬂux was 4.5 (0.6) ng/h
(n = 58; P = 0.0006).
The major results of the study are summarized in Fig. 6, with full
results presented in Supplementary Table 6. The presence of
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Fig. 5 Derived Aβ mass ﬂuxes. Importance of CSF-based clearance increases with age largely due to changes in clearance within the ISF. Clearance of: a
Aβ38 and b Aβ40 from brain ISF declined with age in amyloid-negative subjects, but not in amyloid-positive subjects. In contrast, clearance of: c Aβ38 and d
Aβ40 from CSF (and thus also by transfer from ISF to CSF) was weakly correlated with age. e The fraction of Aβ42 cleared by CSF-based processes was
signiﬁcantly lower than that of Aβ38 and Aβ40 in amyloid-positive subjects. This may be due to increased Aβ42 deposition into plaques in amyloid-positive
subjects (Table 1), which may lower the brain ISF/cranial CSF concentration gradient that contributes to ISF-to-CSF clearance. *P < 0.05, ****P < 0.0001. f
The fraction of CSF-based clearance signiﬁcantly increased with age for Aβ38 and Aβ40 in amyloid-negative subjects due to the signiﬁcant decline in
clearance across the blood–brain barrier or by proteolysis (also see Table 1).

amyloid-β plaques is associated with a decrease in the ISF and CSF
concentrations of Aβ42, a decrease in the BBB/proteolysis ﬂuxes of
Aβ42, and an increase in deposition ﬂux of Aβ42 (Fig. 6a, b). In
normal aging (Fig. 6c, d), a decrease in the cortical concentration of
Aβ is predicted by the model, which has been previously observed85.
The ISF-to-lumbar CSF concentration gradient is also predicted to
be greater in younger subjects, associated with a lower Qosc. Much
greater clearance of Aβ42 via BBB/proteolysis is found in younger
subjects, with a smaller increase in CSF-based clearance. These
balance the greater rate of production of APP- > C99- > Aβ42,
perhaps due to greater neuron number reﬂected in the larger volume
of gray matter or due to greater neuronal activity.

Conclusion. The age-related decline in Aβ peptide turnover has
now been ascribed largely to changes in proteolysis and/or
blood–brain barrier transport. While the current model and dataset
cannot distinguish proteolysis from BBB transport, both should
receive enhanced focus as targets for early AD interventions.
Methods
Human studies. The human studies were performed at Washington University in
St. Louis. The studies were approved by the Washington University Human Studies
Committee and the General Clinical Research Center Advisory Committee. Participants completed informed written consent. The current results are from a
subset of 100 subjects who completed the SILK study and MRI imaging scans.
Subject demographics are summarized in Supplementary Table 1.
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Fig. 6 Graphical summary of major results by amyloid status and age. Summary of major ﬁndings. a, b In non-mutation carriers, the presence of amyloid
plaques decreases the CSF and ISF concentration of Aβ42, due to enhanced deposition. This is despite the decreased mass ﬂux across the blood–brain
barrier or due to proteolysis, and a decrease in transfer from ISF to CSF. t test of predicted marginal means at age = 69.9 y: *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. c, d In older amyloid-negative, non-mutation carriers, total gray volume and production of APP are reduced relative to younger
subjects. This decreases the ﬂux toward Aβ peptides, including Aβ42. However, the ISF concentration of Aβ42 is only slightly elevated in younger subjects,
because of greater ﬂuxes across the BBB or due to proteolysis and greater ISF-to-CSF transfer. In younger subjects, the concentration gradient of Aβ42 from
the ISF to lumbar space is larger, due to a smaller Qosc. t test: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. See Supplementary Table 6 for complete
results.
SILK, MRI, and PET. SILK data collection procedures and PET PIB measurements
were previously described1,2. Brieﬂy, subjects received intravenous and intrathecal
lumbar catheters between 7 a.m. and 9 a.m. The collection of samples began
between 8 a.m. and 10 a.m. Time zero CSF and plasma baseline samples were
withdrawn, then 3 mg/kg L-[U-13C6]leucine was given as a bolus for 10 min, followed by a constant infusion of 2 mg/kg/h for the remainder of the ﬁrst 9 h. Blood
samples (12 mL) were obtained hourly for the ﬁrst 16 h and every other hour for
the rest of the experiment (36 h). CSF (6 mL) was withdrawn hourly. The
10

deposition of amyloid plaques was quantiﬁed by [11C]PIB-PET in 77 subjects.
Subjects with mean cortical binding potential (MCBP) score >0.18 were considered
to be amyloid positive. If PET PIB was not available, a lumbar CSF concentration
ratio Aβ42/Aβ40 < 0.12 was considered to be amyloid positive. PET PIB scans were
performed within 3 years before or after the SILK tracer study date. MRI scans (3 T
volumetric T1-weighted) were processed using FreeSurfer version 5.3 as previously
described86. FDA, Center for Devices and Radiological Health, and IT’IS Foundation collected the MRI data used to generate the images in Fig. 687.
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Mass spectrometry. Sample processing and mass spectrometric measurements were
previously described1,2. Brieﬂy, Aβ peptides were immunoprecipitated with a middomain antibody, in the presence of isotope-labeled internal standard peptides.
Concentrations of peptides and fractional isotope labeling were quantiﬁed by LC-MS/
MS analysis on a Xevo TQ-S (Waters) or TSQ Vantage (ThermoScientiﬁc) mass
spectrometer. Isotope-labeled leucine was captured from the blood by cation exchange
chromatography. The N-heptaﬂuorobutyryl n-propyl ester derivative was quantiﬁed
by GCMS (Agilent 6890N GC and Agilent 5973N Mass Selective Detector).

10.
11.
12.

Mathematical model. Model equations were solved numerically in Julia as
described in Supplementary Methods 1. Parameter meaning, values, and sources
are shown in Supplementary Table 7.
The parameters that were ﬁt to the model were: kBPD38, kBPD40, kBPD42, SF38,
SF40, SF42, Qosc, QCSF, kex42. Other parameters were estimated as follows:
1. The volumetric rate of CSF production was QCSF, which was assumed to
arise solely from the choroid plexus. Extravasation of ﬂuid from the
capillaries of the brain parenchyma was not considered in the model. It was
assumed that the concentration of Aβ peptides in newly formed CSF
was zero.
2. VISF represents the volume of brain gray matter ISF, which was 10% of MRIderived total gray volume. Vcranial is the volume of the cranial SAS. VCV is
the volume of the cisterns and ventricles, which are assumed to be in
intimate communication due to oscillatory ﬂow. Nominally, the cervical
spinal volume is VSP1, the thoracic spinal volume is VSP2, and the lumbar
spinal volume is VSP3.
3. CSF was withdrawn from the lumbar catheter at the start of each hour and
the model assumptions are summarized in Fig. 1b–e. The volume of CSF
removed (6 mL) was divided by the time required for withdrawal (assumed
to be 6 min for all subjects, actual range was stated by the practitioners to be
5–10 min). This yielded the volumetric ﬂow rate of VLP/tCSF draw = 60 mL/h,
where VLP is 6 mL and tCSF draw is 0.1 h. It was assumed that the net caudal
ﬂow could not exceed QCSF during CSF withdrawal. If VLP/tCSF draw exceeded
QCSF, which it did for all subjects, it was assumed that the excess ﬂow came
exclusively from a decrease in volume of the lumbar space (VSP3), which has
been observed in humans during lumbar puncture51. The parameter QLP
represented net caudal ﬂow during withdrawal and reﬁll, while Qreﬁll was
used to account for volumetric changes in the lumbar compartment.
4. Following CSF withdrawal, it was assumed that the entirety of QCSF was
used to reﬁll the lumbar volume to its natural dimensions. The time
required to reﬁll the lumbar space was ΔVSP3/QCSF.
5. After the lumbar space was fully reﬁlled, QLP = 0 for the rest of the hour.
However, if a CSF leak was suggested by the lumbar Aβ concentration data,
then QLP = Qleak, where Qleak is a constant during the entire 36–48 h SILK
experiment, unless otherwise modiﬁed to better ﬁt the concentration rise
data. The maximum value for Qleak was assumed to be QCSF. During CSF
withdrawal and lumbar space reﬁlling, it was assumed that the drop in
pressure halted the leak, i.e., Qleak = 0 during withdrawal and reﬁlling.
6. Some concentration-time courses suggested step changes in Qleak during the
study. This might have occurred if the catheter shifted due to a change in the
subject position. In these cases, an initial constant value of Qleak was
changed to another constant value at a certain time to better ﬁt the lumbar
Aβ concentration data.
7. The loss of CSF down spinal nerves, QSN, was modeled as a net ﬂow of CSF
out of each spinal SAS compartment. It was assumed that QSN was divided
equally between cervical, thoracic and lumbar compartments. The full ﬂow
entered the cervical space, but 1/3 QSN left down spinal nerves within the
cervical space, while 2/3 QSN continued into the thoracic compartment. In
the thoracic space, 1/3 QSN left down spinal nerves within the thoracic space,
while 1/3 QSN continued into the lumbar space. The ﬁnal 1/3 QSN left down
spinal nerves in the lumbar space. During removal of CSF and reﬁlling of
the lumbar space, it was assumed that the drop in pressure completely
halted loss of CSF down spinal nerves (QSN = 0). The model-predicted
cisternography half-life was sensitive to QSN. QSN was varied between 5 and
20% of QCSF. The Moriyama et al. model predicted a mean half-life for all
subjects of 20 ± 2.4 h67. The mean cisternography half-life predicted by the
current model best agreed with the Moriyama et al. prediction when QSN
equaled 10% of QCSF (Supplementary Table 8). In a study in sheep, the
average of three methods indicated that 20.6% of CSF was absorbed by
spinal nerves69. Other studies have indicated higher values, e.g., 38% in
resting humans54.
8. The loss of CSF from the cranial space (e.g., at arachnoid granulations, dural
lymphatics, cribriform plate, etc.) was Qcranial = QCSF − QSN − QLP. This
reﬂected that the outﬂow from the cranial space was only a part of the total
CSF produced by the choroid plexus. During CSF withdrawal and reﬁlling,
QSN = 0 and QLP = QCSF, so Qcranial = 0.
9. Qosc and Qglymph represent the oscillatory CSF ﬂow generated by the cardiac
and respiratory cycles but are modeled as steady bidirectional ﬂows instead

13.

14.

15.

of pulsatile ﬂows due to computational and MRI data constraints. In both
cases, mass transport would only occur in the presence of a concentration
difference between compartments.
The exchange compartment was only relevant to Aβ42 and was implemented
as in the previous steady-state model3.
The SILK isotope-labeling data were also scaled by three additional free
parameters, the scaling factors (SF38, SF40, and SF42). These are believed to
account for instrument calibration errors and were previously described1–3.
The Michaelis–Menten rate constants for conversion of APP to C99 + C83
and C99 to Aβ38–42 were determined by Ortega et al56. Because the rate
constants were given in relative units, units for the rate constants were
derived by comparison with the carefully performed study of APP
conversion to C99 (see Supplementary Table 9)57. The production rate of
APP (kf), Vmax,gamma38 and Vmax,gamma42 were determined from solution of
the steady-state equations. An example of labeling kinetics from plasma
leucine to the lumbar SAS is shown in Supplementary Fig. 4.
APP is a transmembrane protein largely expressed by neurons in the brain.
It appears to react with beta-secretase on the cell exterior and gammasecretase within endosomes79, which are both topologically extracellular.
Because the Michaelis–Menten rate constants were determined in cultured
cells in a relative manner56, and for beta-secretase kinetics in an absolute
manner in human temporal cortex preparations57, it was assumed that all of
the rate constant values were applicable to the neuronal plasma membrane
found in cortical tissue. The volume of ISF was assumed to be 10% of the
total gray volume80, and the total gray volume was determined for each
subject by MRI (Supplementary Fig. 5). Aβ peptides were assumed to be
directly released into the ISF and all other species were transmembrane
spanning. The intracellular concentration of Aβ peptides was assumed to be
zero and the volume of endosome/lysosomes to be negligible.
The parameter Qglymph accounts for the exchange of Aβ between CSF and
ISF but was not well deﬁned by the SILK data when set as a free parameter.
The concentration “gradient” [Aβ40]ISF/[Aβ40]lumbar was sensitive to the
glymphatic exchange ﬂow rate parameter (Qglymph). In pilot studies, when
Qglymph was decreased from QCSF to QCSF/2, the lumbar-to-ISF concentration
rise increased from 9.6 ± 6.9 to 14 ± 11. Further decreasing Qglymph by setting
it equal to Qosc (slightly less than QCSF/2) resulted in a lumbar-to-ISF
concentration rise of 71 ± 130. Given the similarity between Aβ concentrations measured in homogenized cortex and CSF, lower values of Qglymph
were ruled out and Qglymph was set equal to QCSF for all subjects. The
governing assumption was that soluble Aβ exists entirely in ISF and that
homogenization of cortical tissue dilutes the ISF about tenfold with
intracellular ﬂuids, thus decreasing the measured concentration by a factor
of 10. With this assumption, cortical ISF concentrations are predicted to be
tenfold higher than those measured in the homogenized cortex. In the ﬁnal
model with Qglymph = QCSF, the mean lumbar-to-ISF concentration rise was
10 ± 6.6.
For each equation shown (except for dVSP3/dt), isotopically labeled and
unlabeled peptides were modeled separately. The APP production rate (kf)
was scaled by fLeu (the fraction of labeled leucine) for production of labeled
APP, and scaled by (1 − fLeu) for production of unlabeled APP. It was
assumed that the fraction of labeled leucine in ISF was the same as the
fraction of labeled leucine in plasma, which was measured hourly for the
ﬁrst 13 h, then at 17 and 35 h. The tail of the plasma leucine labeling curve
was ﬁt to an exponential model2.

Statistics and reproducibility. Statistical analyses were performed in R and
comparisons were by two-sided t test with unequal variances or ANOVA with
Tukey post hoc analysis. Errors are standard deviations except where noted. Box
plots show: center line = median; box limits = upper and lower quartiles; whiskers = 1.5× interquartile range; points = outliers. Conﬁdence interval region =
95%. Measurements were taken from distinct samples. Replicates are biological
replicates.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
De-identiﬁed source data (Supplementary Data 1) and model results (Supplementary
Data 2 and 3) are included in the Supplementary Materials.

Code availability
Code deposited at https://zenodo.org/badge/latestdoi/437570053.
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